Indicated for continuous monitoring with an insertable cardiac monitor

Willing to be implanted in an office setting with only local anesthetic available

Able to understand the nature of the study and provide informed consent

Able and willing to complete all routine follow-up visits at the study site for the expected 90-day follow-up

Able and willing to use a CardioMessenger® capable of communicating with the BioMonitor 2

Age greater than or equal to 18 years

At the time of insertion, the following pre-procedure criteria must be met for the subject to undergo insertion:

Most recent INR value (within 7 days) is less than 3.5 if currently taking warfarin

Absence of infection with no history of infection within the last 30 days

BioMonitor 2 In-Office Setting Insertion Safety and Feasibility Evaluation With Device Functionality Assessment